Folate functionalized gold-coated magnetic nanoparticles effect in combined electroporation and radiation treatment of HPV-positive oropharyngeal cancer
Abstract The rate of HPV-positive oropharyngeal cancer incidence is increasing, especially in the young population. While these patients show good responses to radiotherapy. The major complication of radiotherapy is normal tissue involvement. Thus, finding an effective treatment method is essential. Multimodal therapy with the lowest side effect could be an effective treatment method. Theranostic gold magnetic core–shell nanostructure was developed as a platform for multimodal therapy of HPV-positive oropharyngeal cancer. The folate functionalized gold-magnetic core–shell nanostructure has been synthesized in a stepwise approach and characterized with various techniques including TEM, UV–Vis, and FTIR spectroscopy. KB was selected as a host for HPV and folate receptor-positive cancer. HGF as normal cell lines was selected. Both cell lines have been treated with nanoparticles, electric field and radiotherapy, either separately or in combination. Cell viability and apoptosis rate were determined by MTT and flow cytometry assay. In addition, cellular uptake of the nanoparticles was measured by ICP-OES analysis. The average size of folate functionalized gold-magnetic core–shell nanostructure was 13.8 ± 6.4 nm. A characteristic plasmonic peak of gold nanoshells was observed in the UV–Vis spectrum. The functionalization of synthesized nanostructure was confirmed with FTIR spectroscopy. None of the treatments alone can cause a significant death in cancerous cells. Combination treatments can increase cancer cell mortality and increase the proportion of apoptotic cells in them. Furthermore, it has been observed that the electric field enhanced the cellular uptake of nanoparticles just in cancerous cells. Based on our findings, we conclude that the combination of folate functionalized nanoparticles and electroporation opens a new way to improve radiation therapy efficacy of HPV-positive cancers..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Medical oncology - 39(2022), 12 vom: 07. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahmadi Kamalabadi, Mahdieh [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Electroporation |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s12032-022-01780-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048026409 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048026409 | ||
| 003 | DE-627 | ||
| 005 | 20230519093000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12032-022-01780-2 |2 doi | |
| 035 | |a (DE-627)SPR048026409 | ||
| 035 | |a (SPR)s12032-022-01780-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahmadi Kamalabadi, Mahdieh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Folate functionalized gold-coated magnetic nanoparticles effect in combined electroporation and radiation treatment of HPV-positive oropharyngeal cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
| 520 | |a Abstract The rate of HPV-positive oropharyngeal cancer incidence is increasing, especially in the young population. While these patients show good responses to radiotherapy. The major complication of radiotherapy is normal tissue involvement. Thus, finding an effective treatment method is essential. Multimodal therapy with the lowest side effect could be an effective treatment method. Theranostic gold magnetic core–shell nanostructure was developed as a platform for multimodal therapy of HPV-positive oropharyngeal cancer. The folate functionalized gold-magnetic core–shell nanostructure has been synthesized in a stepwise approach and characterized with various techniques including TEM, UV–Vis, and FTIR spectroscopy. KB was selected as a host for HPV and folate receptor-positive cancer. HGF as normal cell lines was selected. Both cell lines have been treated with nanoparticles, electric field and radiotherapy, either separately or in combination. Cell viability and apoptosis rate were determined by MTT and flow cytometry assay. In addition, cellular uptake of the nanoparticles was measured by ICP-OES analysis. The average size of folate functionalized gold-magnetic core–shell nanostructure was 13.8 ± 6.4 nm. A characteristic plasmonic peak of gold nanoshells was observed in the UV–Vis spectrum. The functionalization of synthesized nanostructure was confirmed with FTIR spectroscopy. None of the treatments alone can cause a significant death in cancerous cells. Combination treatments can increase cancer cell mortality and increase the proportion of apoptotic cells in them. Furthermore, it has been observed that the electric field enhanced the cellular uptake of nanoparticles just in cancerous cells. Based on our findings, we conclude that the combination of folate functionalized nanoparticles and electroporation opens a new way to improve radiation therapy efficacy of HPV-positive cancers. | ||
| 650 | 4 | |a Head and neck cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Human papillomavirus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Gold-coated magnetic nanoparticles |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Electroporation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Radiotherapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Neshastehriz, Ali |4 aut | |
| 700 | 1 | |a Ghaznavi, Habib |4 aut | |
| 700 | 1 | |a Amini, Seyed Mohammad |0 (orcid)0000-0001-6447-9872 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical oncology |d New York, NY : Springer, 1984 |g 39(2022), 12 vom: 07. Sept. |w (DE-627)SPR023865016 |w (DE-600)2008172-8 |x 1559-131X |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2022 |g number:12 |g day:07 |g month:09 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12032-022-01780-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2022 |e 12 |b 07 |c 09 | ||